• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Poland·Healthcare·MDG.WA
Share

Medicalgorithmics S.A. Stocks

PLN 26.25Last Updated 11.09.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

PLN 74.42M

PLN 26.25
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 2005 and headquartered in Warsaw, Poland, Medicalgorithmics S.A. is a prominent provider of cardiac diagnostic solutions, serving markets in Poland, the United States, and globally. The company offers an array of advanced products, including PocketECG, a comprehensive diagnostic system for arrhythmia detection that furnishes detailed ECG signals, data analysis, and exhaustive reports. Another key offering is PocketECG CRS, specifically designed for monitoring patients during cardiac rehabilitation. Its technological portfolio also encompasses ECG TechBot, a software program that utilizes algorithms for the automated analysis and interpretation of ECG signals, and PatchECG, a device enabling single-channel, offline heart monitoring. Additionally, PocketECG IV enhances the core PocketECG device by enabling continuous ECG signal transmission via LTE connectivity. Beyond its innovative devices, Medicalgorithmics S.A. delivers services in information technology, biotechnology, ECG monitoring, and scientific research and development, alongside manufacturing and distributing electro-medical equipment.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is 'expensive' on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of MDG.WA is 42.8 and suggests 61.2% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.09.2026 00:58

Data from some Revolut customers was leaked

12.09.2026 16:01

Small caps last week: Chewy's earnings miss, Signet's best day ever, AE rethinks ads

12.09.2026 13:01

The iPhone Reboot, the AGI Era, and Silicon Valley's Right Turn

12.09.2026 05:06

Spam from OpenAI's AI agents disrupted the developer service for four days

12.09.2026 03:52

Citrini, the founder who spooked the market with his prediction of AI threats, has sold the company. What's next?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026